| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 0.60 | 0.02 (+3.45%) | 0.4901 - 3.21 | 244.4 thousand (Below Avg) |
Market data as of 4:00PM 05/21/13. Quotes are delayed by at least 15 min.
| Open | 0.58 |
|---|---|
| Previous Close | 0.58 |
| Day's Range | 0.58 - 0.61 |
| Market Cap | 91.6M |
| Avg Volume (10 Day) | 567.3K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.69 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
PR Newswire - Monday 05/13/2013 5:23 PM ET
Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
PR Newswire - Tuesday 05/07/2013 4:30 PM ET
Anthera Announces First Quarter 2013 Financial Report and Conference Call
PR Newswire - Friday 05/03/2013 2:06 PM ET
| ANTH | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.55 | |
| LT Debt/Equity | 0.26 | |
| Earnings Yield | -- | |
| Price/Sales | -- |
| Company | Last | Change |
|---|---|---|
| Rockwell Medical Inc | 3.87 | +9.94% |
| Ventrus Biosciences Inc | 2.66 | +1.53% |
| Alimera Sciences Inc | 4.42 | +0.91% |
| KaloBios Pharmaceuticals Inc | 5.85 | +0.86% |
| Echo Therapeutics Inc | 0.48 | +0.42% |
Data is delayed by at least 15 min.